Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06686602 · ClinicalTrials.gov registry record
A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer
A clinical trial of Advanced/Metastatic NSCLC and Advanced/Metastatic HER2-negative Breast Cancer, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 13,759
- Enrollment target
- 1
- Study location
NCT06686602: Completed study of Advanced/Metastatic NSCLC and Advanced/Metastatic HER2-negative Breast Cancer, sponsored by Daiichi Sankyo.
NCT06686602 is a study of Advanced/Metastatic NSCLC and Advanced/Metastatic HER2-negative Breast Cancer that has completed, run by Daiichi Sankyo. The registered enrollment target is 13,759 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06686602, a study of Advanced/Metastatic NSCLC and Advanced/Metastatic HER2-negative Breast Cancer, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 13,759 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will identify risk factors for oral mucositis/stomatitis and ocular surface events (OSE) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) and advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
Conditions Studied
Interventions
- OTHER No drug
Study Locations (1)
Massachusetts
- ConcertAI Database - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,759 participants |
| Start Date | 2024-07-09 |
| Est. Completion | 2025-03-18 |
What the finished NCT06686602 record still lists
NCT06686602 is an observational study that tracks outcomes without assigning an intervention. Its 13,759 participants enrollment target places it among the larger protocols in the corpus.
The record links to 2 conditions, with Advanced/Metastatic NSCLC appearing as the primary indexed condition, and to 1 intervention - of which No drug is the first listed.
NCT06686602 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06686602 about?
NCT06686602 is a clinical study titled "A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer". This study will identify risk factors for oral mucositis/stomatitis and ocular surface events (OSE) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) and advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
What is the current status of trial NCT06686602?
This trial is currently completed. The enrollment target is 13,759 participants. The study started on 2024-07-09. Estimated completion is 2025-03-18.
What conditions does trial NCT06686602 study?
This clinical trial studies the following conditions: Advanced/Metastatic NSCLC, Advanced/Metastatic HER2-negative Breast Cancer.
What interventions are being tested in trial NCT06686602?
The interventions under investigation include: No drug (OTHER).
Who is sponsoring clinical trial NCT06686602?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06686602 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced/Metastatic NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058767 · 13,764 participants · NA
Preschool Hearing Screening
- NCT05141396 · 13,400 participants · NA
Telehealth-Enabled, Real-time Audit and Feedback for Clinician AdHerence (TEACH)
- NCT05591066 · 14,400 participants · NA
The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now
- NCT05991453 · 13,000 participants · NA
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI